Sponsor:
Alnylam Pharmaceuticals
Code:
NCT04883905
Conditions
Acute Hepatic Porphyria
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Brief summary:
Conditions
Acute Hepatic Porphyria
Study ID
NCT04883905
Start date
Apr 26, 2021
Status verified date
Sep, 2026
Completion date
Dec 31, 2030
Anticipated
Primary completion date
Dec 31, 2030
Anticipated
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Enrollment
150 participants
Anticipated
Arms
Patients with AHP
Primary outcome measure
Central contacts
Locations
Clinical Trial Site
Recruiting
Birmingham, Alabama, United States, 35233
Clinical Trial Site
Recruiting
Gilbert, Arizona, United States, 85234
Clinical Trial Site
Recruiting
San Francisco, California, United States, 90074
Clinical Trial Site
Recruiting
Baltimore, Maryland, United States, 21205
Clinical Trial Site
Recruiting
Boston, Massachusetts, United States, 02114
Clinical Trial Site
Recruiting
Minneapolis, Minnesota, United States, 55455
Clinical Trial Site
Recruiting
New York, New York, United States, 10029
Clinical Trial Site
Recruiting
Oklahoma City, Oklahoma, United States, 73120
Clinical Trial Site
Recruiting
Galveston, Texas, United States, 77555
Clinical Trial Site
Recruiting
Salt Lake City, Utah, United States, 84112
Clinical Trial Site
Recruiting
Seattle, Washington, United States, 98195
Sponsor
Alnylam Pharmaceuticals
Last update posted
Sep 8, 2026
Last verified
Sep, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Alnylam Pharmaceuticals on 2026-09-08.